IP Library › Granted Patent US 12,121,577
Granted Patent B1
US 12,121,577 · App. 18/606,473 · Granted Oct 22, 2024

mRNA treatment nanoparticles

Inventors: Samuel Deutsch (Walnut Creek, CA); Daniel Frimannsson (Alameda, CA); Nicole Fay (Alameda, CA); Colin McKinlay (Fremont, CA); Ole Haabeth (Emeryville, CA)
Assignee: Nutcracker Therapeutics, Inc.
A61K39/12A61P35/00A61K2039/53A61K2039/54A61K2039/55522A61K2039/55538A61K2039/892
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,121,577
App. No.
18/606,473
Granted
Oct 22, 2024
Kind
B1
Abstract

Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.

Claims (12)

1. A therapeutic mRNA composition comprising:

a first mRNA scaffold comprising a first mRNA coding region encoding HPV16 E6 E7;

a second mRNA scaffold comprising a second mRNA coding region encoding an interleukin-12 (IL-12), wherein the IL-12 comprises the amino acid sequence of SEQ ID NO: 6; and

a third mRNA scaffold comprising a third mRNA coding region encoding a tumor necrosis factor superfamily member 14 (TNFSF14), wherein the TNFSF14 comprises the amino acid of SEQ ID NO:12, and

wherein the first mRNA scaffold, the second mRNA scaffold, and the third mRNA scaffold are encapsulated in a delivery vehicle; and

wherein the delivery vehicle is selected from the group consisting of lipid nanoparticles, polymer-based nanoparticles, cationic lipids, ionizable lipids, amino-lipidated peptoids, amphipathic molecules/nanoparticles, and tertiary amino lipidated cationic peptoids.

2. The therapeutic mRNA composition of claim 1 , wherein the first mRNA scaffold and the second mRNA scaffold are encapsulated in a single delivery vehicle.

3. The therapeutic mRNA composition of claim 1 , wherein the first mRNA scaffold, the second mRNA scaffold, and the third mRNA scaffold are encapsulated in a single delivery vehicle.

4. The therapeutic mRNA composition of claim 1 , wherein the TNFSF14 is wild type TNFSF14.

5. The therapeutic mRNA composition of claim 1 , wherein the therapeutic mRNA composition is an mRNA nanoparticle, an mRNA treatment nanoparticle, or a vaccine.

6. The therapeutic mRNA composition of claim 1 , wherein the therapeutic mRNA composition is configured to be administered to a subject known to have cervical cancer.

7. The composition of claim 1 , wherein the therapeutic mRNA composition is configured to be injected intratumorally.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2026
From: NUTCRACKER THERAPEUTICS, INC.
To: MEDICI THERAPEUTICS, INC.
Reel/Frame 074407/0426 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2024
From: DEUTSCH, SAMUEL; FAY, NICOLE; FRIMANNSSON, DANIEL; HAABETH, OLE; MCKINLAY, COLIN
To: NUTCRACKER THERAPEUTICS, INC.
Reel/Frame 068519/0889 →
Continuity (4)
Continuation 18520449 · Nov 27, 2023
Continuation 18048390 · Oct 20, 2022
Continuation PCTUS2021028312 · Apr 21, 2021
Provisional Application 63014074 · Apr 22, 2020